KAPA Kairos Pharma, Ltd.

-

Kairos Pharma, Beat Consensus Estimates

Friday, November 13, 2026 · 12:00 AM ET

Kairos Pharma, (KAPA) reported a loss of $0.59 per share on revenue of $0.00 million for the third quarter ended September 2026. The consensus estimate was a loss of $0.63 per share. The company beat consensus estimates by 6.35%.

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focused on developing a diversified pipeline of cutting-edge oncology therapeutics born from structural biology to reverse cancer drug resistance and the inhibitory effects of cancer on the immune system. Kairos Pharma Ltd. is based in Los Angeles, California.

Earnings Whisper Grade —
Power Rating—
Reported Earnings
($0.59)
Earnings Whisper®
—
Consensus Estimate
($0.63)
Earnings Surprise
Earnings Growth-20.4 %
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—